[US Stock Movement] First Tracks surged on October 12: ANB033 positive + celiac disease

First Tracks October 12 Major Surge Interpretation

Keywords: ANB033 positive, celiac disease

1. On October 12, the company announced the topline results of the ANB033 celiac disease Phase 1b trial Cohort 1: the change from baseline in the villous height to crypt depth ratio was -0.17, compared to -0.66 for placebo, with a placebo-corrected difference of +0.49, p=0.009; the change in IEL density was -1.20, compared to +18.83 for placebo, with a placebo-corrected difference of -20.03, p<0.001. Furthermore, no increase in symptoms was observed throughout the gluten challenge period, and no safety signals have been observed to date.

2. On August 12, the company disclosed that enrollment for Cohort 1 of the ANB033 celiac disease Phase 1b trial had been completed and that it had received Fast Track designation from the U.S. FDA; the company’s pipeline also includes ANB033 for eosinophilic esophagitis, rosnilimab and ANB101 for rheumatoid arthritis, and cash reserves are expected to last until Q2 2028.

(Disclaimer: This content is generated and summarized by AI technology from publicly available information and is for reference only. It does not constitute investment advice.)